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Strokei s the third-leading cause of death in the Western world, trailing only heart disease and cancer. Nearly 700,000 new strokes occur in the United States annually. 1 Approximately 60 -80% survive stroke. In the United States, there are about 1.7 million survivors with disabilities, costing society over $7 billion/yr. 2 Hemiparesis is the most common deficit after stroke, affecting Ͼ80% of subjects acutely and Ͼ40% chronically. 3 Rehabilitation techniques have been more successful in restoring function in the lower limb than in the upper limb. 4 Unfortunately, upper-limb function is more important for independent living and self-esteem. 5, 6 The time course of upper-limb recovery has been placed at 11 wks after stroke, after which "further recovery of upper extremity function should not be expected." 7 Fortunately, the pessimism regarding recovery of upper-limb function has been convincingly challenged by a number of emerging behavioral therapies, including neuromuscular electrical stimulation, robot-aided sensory motor stimulation, real-time auditory feedback, and repetitive bilateral arm training with rhythmic auditory cuing. 8 -12 Constraint-induced movement therapy (CIMT) has attracted great attention because of its demonstrated efficacy, its sound physiologic principles, and evidence attesting that it stimulates cortical plasticity. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] However, to benefit from CIMT, eligible patients must meet a "minimum motor criterion" of 10 degrees of volitional extension of the wrist, 10 degrees of volitional abduction of the thumb, and 10 degrees volitional extension of two other digits in 3 mins. 14 -17 It has been estimated that 25% of stroke survivors can meet the minimal motor criteria. Unfortunately, this leaves a large number of affected individuals ineligible for CIMT. We have observed that many with stroke who are unable to meet the minimum motor criteria also exhibit spasticity in the upper limb.
Despite clinicians' great familiarity with spasticity as a possible consequence after stroke, there is a paucity of information regarding its prevalence and its clinical significance. Limitations include reliance on clinical scales such as the Modified Ashworth Scale (MAS), lack of measurement of cocontraction, and reliance on global functional measurements that may lack the sensitivity to detect more subtle impairments. Watkins et al. 23 applied the MAS and the Tone Assessment Scale to 106 individuals who were 1 yr post stroke; they found the prevalence of spasticity to be 40%. They note that those with spasticity also had significantly lower scores on the Barthel Index and were more likely to live in institutional settings than in their own homes. Sommerfeld et al. 24 used the MAS to measure spasticity in 95 individuals at 3 mos after stroke. They found spasticity in 19% of their sample. However, the incidence rose to 28% of those with hemiparesis. At 3 mos, higher upper-limb scores on the MAS were correlated with worse performance on the Birgitta Lindmark Motor Assessment Active and Rapid Movement scores and the Nine Hole Peg Test. Although these studies add to our knowledge of poststroke spasticity, the true incidence, prevalence, and significance of poststroke spasticity have yet to be established.
Since 1989, a number of studies have demonstrated botulinum toxin A (BTX-A) as a safe, effective treatment to reduce upper-limb spasticity caused by stroke or traumatic brain injury. [25] [26] [27] [28] These studies make it clear that BTX-A-induced tone reduction can result in improved upper-limb function by easing passive manipulation of the plegic or paretic limb. Although a careful reading of the literature reveals intriguing hints, the question of whether judicious use of BTX-A can facilitate the restoration of volitional control of the hand remains unanswered. 29 -33 Could the existence of hypertonus and cocontraction mask a latent ability to extend and control the wrist and fingers for those who have spasticity after stroke? Could a combination of BTX-A plus exercise therapy reduce tone and, thus, reveal hidden hand movement?
We postulated that for individuals with poststroke upper-limb hemiparesis and spasticity who could not perform the minimum motor criteria to qualify for CIMT:
1. Treatment with BTX-A and then 4 wks of exercise therapy would reduce tone and impairment as measured by the Ashworth and Fugl-Meyer upper-extremity scales. 34 -35 2. Treatment with BTX-A and then 4 wks of evidence-based exercise therapy would improve volitional control sufficiently to meet minimum motor criteria more than would be expected by chance alone. 3. The ability to volitionally extend the wrist, fingers, and thumb at baseline would identify those who would be able to meet CIMT criteria from those who could not.
We also wished to explore the feasibility of using BTX-A plus exercise therapy combined with CIMT to improve hand function after stroke. We expected that any gains achieved during CIMT would diminish in the next 18 wks as spasticity returned.
As a preliminary trial, we were aware that the relatively small enrollment would provide insufficient statistical power to adequately test hypotheses on the basis of group differences. There would almost certainly be an unacceptable risk of committing a type 2 error (supporting a false-null hypothesis). Nonetheless, we thought it would be valuable to gather preliminary information from which appropriate hypotheses with adequate power could be generated for future studies. Therefore, we collected data comparing performance of those who met the minimal motor criteria with those who did not on the Wolf Motor Function Test (WMFT), the Motor Activity Log (MAL), the Box and Blocks Test (BBT), and the upper-extremity subtest of the Fugl-Meyer Assessment of Motor Function (FM-UE), for descriptive purposes. These data did not undergo statistical analysis. [35] [36] [37] [38] [39] 
METHODS Participants
Twelve subjects (Ն21 yrs of age) with unilateral strokes were recruited through flyers from primary care, neurology, and physical medicine and rehabilitation clinics, and from a research screening database. As inclusion criteria, all participants must have exhibited hand paresis after a unilateral stroke at least 90 days earlier and have been unable to meet minimal motor criteria for CIMT (unable to achieve 10 degrees of voluntary extension of the wrist, 10 degrees of abduction at the thumb, and 10 degrees of extension of two fingers in the affected hand, repeated three times in 1 min). Further, potential participants must have displayed hypertonus at rest (Ն2 on the Ashworth Scale at the wrist, fingers, or thumb) or evidence of deleterious cocontraction (e.g., finger or wrist flexion during attempted hand opening). Participants must have reached a plateau regarding hand func-tion. Specifically, the participants must not have been experiencing improvement or decrement in active hand function. Exclusion criteria included the following: ability to meet minimal criteria for participation in CIMT; active participation in conventional therapy for upper-limb dysfunction; joint immobility in the upper limb attributable to contracture, bony deformity, or heterotopic ossification; history of clinically apparent stroke in the contralateral hemisphere, or more than minor stroke in the contralateral hemisphere on imaging studies; history of major head trauma, dementia, learning disorder, schizophrenia, or major depression before the stroke; medical instability; known allergy to BTX-A; and current receipt of BTX-A treatment. This study was approved and monitored by a university institutional review board and a subcommittee on clinical investigations. All subjects provided informed consent to participate.
Design
The experimental design is illustrated in Figure 1. Subjects who met eligibility criteria for CIMT at the conclusion of exercise therapy were entered into a 2-wk course of CIMT.
Treatment

Botulinum Toxin
Doses and muscles selected for BTX-A injection were individualized on the basis of a number of factors, including the patient's weight, the amount of resistance to passive stretch, and the degree of cocontraction present when the participant attempted to extend the wrist and fingers. 40 total dose of up to 400 U of BTX-A was used. Botox brand BTX-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) was prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 25 U/ml. 41 This created a more dilute solution than is used in some clinical settings. Although this requires larger volumes, with a possibility of spread to nontargeted adjacent muscles, several reports in humans and animals support a greater effect of more diluted solutions. [42] [43] [44] [45] [46] Location of the targeted muscle was confirmed by use of an electrically active hypodermic needle (EZstim Model ES300, Life-tech, Inc, Stafford, TX). Between 20 and 75 units of BTX-A per muscle were injected into the flexor carpi ulnaris and flexor carpi radialus; 12.5-25 units per fascicle in the flexor digitorum sublimis and flexor digitorum profundus (maximum dose: 100 units for each of these muscles); 10 -30 units in the flexor pollicis longus; 25-100 units in the brachioradialus; 50 -200 units in the biceps brachii; and 25-75 units in the pronator teres. The greatest volume used for a single injection of the flexor carpi radialus, flexor carpi ulnaris, or pronator teres was 1.5 ml; for the flexor digitorum sublimis and flexor digitorum profundus, the greatest volume was 1 ml per fascicle; 1.2 ml was the maximum used for the flexor pollicis longus; and 2 ml was the maximum for the brachioradialus and biceps brachii. Thus, most subjects received more than one injection in at least some of the targeted muscles.
Exercise Therapy
The application of exercise therapy after botulinum toxin treatment for the upper limb is the norm in both clinical trails of BTX-A and in clinical practice. In fact, BTX-A treatment is so often coupled with exercise therapy that the independent effects of BTX-A treatment alone, vs. those of therapy alone, vs. those generated by the combination of the two, are unknown. To complicate matters, there exists no standard regimen of exercise therapy that is widely applied after BTX-A injection of the upper limb. A postinjection therapy was created for this protocol, commencing within 1 wk of BTX-A treatment. Its intensity was 1 hr, three times per week, with a duration of 4 wks, consistent with most current U.S. reimbursement policies. The content of therapy was built around three evidence-based physiotherapeutic concepts for improving arm and hand function in stroke patients, as elucidated by Waldag and Hummelsheim 13 : (1) multiple motor repetitions of behaviorally meaningful task practice, (2) accurate feedback, and (3) mental practice. Operationally, this translated to a progressive program of repeated motor practice built on the elements of functional grasp, reach, and release movements. As subjects gained mastery of sim-pler tasks, tasks with increasing complexity were introduced. For participants lacking the capacity to actively engage in task-oriented exercise, the therapists provided active-assist and passive movements. Therapists also emphasized relaxation to allow release for those who were unable to actively release despite training and BTX-A treatment. Therapists were trained to give specific feedback regarding the accuracy and speed of movements. When actual task practice was not taking place, participants were instructed to visualize restored function of their impaired upper limbs and to imagine the kinesthetic sensations that would be involved in normal movement of the impaired upper limb. All participants received instruction to continue the exercise program initiated in the clinic at home. Participants were encouraged to incorporate the paretic limb in ordinary home activities as much as possible, emphasizing wrist and finger extension.
CIMT
CIMT consisted of 6 hrs of intensive upperlimb training 5 days/wk for 2 wks, carried out by therapists who completed instruction at the University of Alabama. CIMT included massed repetition, task practice with shaping (approach of a desired motor or behavioral objective by small steps and successive approximations), and intensive timed activities. The daily interventions were designed around a menu of functional activities that incorporated variations of strength, endurance, coordination, dexterity, and range of motion. Interest inventories and role checklists were used to incorporate the participant's unique personality traits and interests into the menu. Typical activities included tasks such as bag toss at a target, reaching and grasping selected objects used in daily life, stacking and moving checkers, turning pages, card activities, writing on and erasing on a chalk board, and preparing and eating lunch. The participants gave daily input regarding the activities they performed in the laboratory and when they returned home or to the motel. In this way, a variety of purposeful and meaningful activities were incorporated, with attention to unique limitations. Encouragement was provided continuously. Therapists sought to prevent participants from failing, by providing assistance as necessary or changing the task. If an activity was strongly disliked or seemed to be too difficult, it was eliminated from the menu for the next day. Participants were instructed to wear a restrictive mitt on the nonparetic hand during 90% of their waking hours. The mitt was removed only for safety, hygiene, or agreed-on activities, as documented in daily diaries. The tasks requiring mitt removal were then focused on during the next CIMT session.
Baseline Measures
At baseline, all participants were evaluated for the amount of volitional control present in the hemiparetic limb. Participants were seated comfortably in a chair with their forearms supported by an armrest and their wrists placed unsupported. Participants were asked to maximally extend their wrists against gravity three times in 1 min. They were then asked to extend their fingers maximally, three times in 1 min. Finally, they were asked to extend their thumbs three times in 1 min. Determination of the range of motion was made by physical and occupational therapists measuring the maximal excursion of the segment. Participants were encouraged to give their best efforts, and they were given the opportunity to warm up and to passively range their hands. Any participant whose performance came close to meeting the minimum motor criteria was examined repeatedly, to confirm a true inability to meet criteria, before being included in the study. The presence or absence of voluntary extension or abduction was recorded dichotomously as either present or absent in the wrist, thumb, and all four fingers. The segment was rated as present if the movement exceeded or was equal to active movement with gravity eliminated.
Outcome Measures
Outcome measures consisted of the Ashworth Scale, FM-UE, BBT, WMFT, and the MAL. The Ashworth was chosen as a common, easily applied method to assess hypertonus. Each participant was sat upright in a chair with the elbow flexed at approximately 90 degrees resting on an armrest, and the wrist dangling comfortably at approximately 30 degrees of flexion off the end of the armrest. To standardize the resting activity state within and between subjects, each subject was instructed to squeeze a tennis ball in the nonplegic limb for 5 secs and then to relax for 5 secs. This was repeated for a total of five times. Then, two examiners rated each participant at the elbow, wrist, fingers, and thumb, and repeated this procedure until consensus was reached. The FM-UE was chosen to measure of severity of impairment. Participants were carefully evaluated for hypertonus and cocontraction. The BBT was chosen as a simple test of the ability to grasp and release, which was the primary behavior targeted in therapy during the 4-wk period after BTX-A injection. The MAL was chosen as a measure of self-reported use of the paretic hand in daily life tasks, and the WMFT was chosen as a measure of fine and gross motor facility of the upper limb. The WMFT and MAL were not obtained before BTX-A injection because these subjects had so little function of the paretic upper limb at baseline.
Statistics
Results were tested using repeated-measures analysis of variance. The figures presented do not reflect correction for multiple comparisons.
RESULTS
The average age of the 12 participants was 56.2 (SD ϭ 15), and the average time since the stroke was 46.8 mos (SD ϭ 26). The participants presented with a variety of strokes in a variety of locations; doses of BTX-A applied ranged from 287.5 to 400 units (Table 1 ).
Relationship Between BTX-A Treatment and 4 wks of Exercise Therapy and Resting Tone and Impairment
Mean Ashworth scores at baseline were: elbow 1.75, wrist 1.91, fingers, 2.58, thumb 1.67. At 4 wks, mean Ashworth scores declined to elbow 1.08, wrist 1.00, fingers 1.58, thumb 1.08. A mean Ashworth value for all four joints (wrist, elbow, thumb, and fingers) was calculated. Comparison of baseline mean Ashworth Scale scores with that achieved after 4 wks of exercise therapy showed a significant decrease from a mean score of 2.0 to a mean score of 1.2 (P ϭ 0.01). No significant change was seen in the FM-UE, which was 21 at baseline and 23.8 at 4 wks ( Figs. 2 and 3 ).
Effect of BTX-A and 4 wks of Evidence-Based Exercise Therapy on Ability to Meet Minimum Motor Criteria
Spontaneous recovery of motor control of the hand is clearly a rare event in chronic stroke. Olsen 47 studied recovery from stroke for 3 yrs after onset and found that best upper-limb function was achieved by 95% of patients by week 14. Parker et al. 48 found that only 13% of those with upper-limb hemiparesis had a change in function between 3 and 6 mos after stroke. Wade et al. 49 found improvement in just 6.3% in those with severe upperlimb impairment between the 6 and 12 mos after stroke, and this diminished thereafter. We conservatively chose the value of a 10% rate of spontaneous recovery during 4 wks to make statistical comparisons. Four of the 12 subjects were able to achieve minimal motor criteria for CIMT during the 4-wk program of BTX-A plus exercise therapy. This reached statistical significance (P ϭ 0.026).
The predictive value of the ability to volitionally extend the fingers against gravity at baseline was used to discriminate those who would be able to meet CIMT criteria from those who could not. Of the participants who met minimum motor criteria for CIMT after BTX-A treatment plus exercise therapy, three of the four were able to extend at least three of four fingers against gravity at baseline (before BTX-A and exercise therapy). No partici-pant with movement in at least three of four fingers failed to meet minimum motor criteria after BTX-A and 4 wks of exercise therapy. Of the participants who were initially unable to generate any movement in any of the fingers, eight of the nine failed to meet minimum motor criteria after BTX-A and exercise therapy. Therefore, movement in three of four fingers predicted the ability to reach minimal motor criteria, with a sensitivity of 75% and a specificity of 100%. The positive predictive value of this criterion was also 100%. All subjects who were able to move at least three of four fingers were also able to move the thumb and wrist. However, the one participant who was able to move his or her thumb despite having no finger or wrist movement, and the two participants who were able FIGURE 2 Summed Ashworth scores. to move their wrists, but neither fingers nor thumb, were unable to meet minimal motor criteria for CIMT ( Table 2 ).
The Effect of CIMT on Volitional Control
Four participants met minimal motor criteria. One was lost to follow-up before the start of CIMT because of health reasons unrelated to the study. A second participant received CIMT for 1 wk and then withdrew from CIMT treatment. This participant found wearing a mitt at home too burdensome and embarrassing as she tried to care for her young children. However, she displayed significant improvement from baseline during the week of CIMT, and she agreed to attempt to use her paretic hand during her daily life and to continue to follow up for assessment as scheduled. For the purposes of analysis, she was grouped with the two individuals who had completed CIMT. Two subjects who did not meet MMC failed to return for follow-up beyond the sixth week of the study. Data from a third subject were not included after the fourth week because of deviation from the experimental protocol. Performance of the three participants who were enrolled in CIMT showed improvement after 2 wks of CIMT. The number of blocks moved during the BBT increased from a mean of 4.25 after 4 wks compared with a mean of eight blocks after CIMT. The differences between the mean selfreport score on the MAL-Amount of Use increased from 1.12 (very rarely using the weaker arm) to 1.93 (rarely used the weaker arm). Time on the WMFT decreased from a mean time of 41.6 to 32.9 secs-a 21% improvement for those who participated in CIMT ( Figs. 4-6 ).
Duration of Treatment Effect, Return of Spasticity
By the 24th week, spasticity had largely reasserted itself. The mean Ashworth score at the elbow was 1.44, at the wrist 1.44, for the fingers 2.55, and at the thumb 1.11. The summed Ashworth score rose to 1.68 (SD 0.37), nearing the initial pre-BTX-A baseline measurement (P ϭ 0.01). Initial improvements in the BBT, WMFT, and MAL had all reverted by the 24th week.
DISCUSSION
This preliminary investigation yielded many findings of interest. However, conclusions drawn from this study must be tempered by the many limitations inherent in its design. These include a relatively small sample size, omission of functional measures at baseline such as the WMFT and the MAL, reliance on the Ashworth Scale as the only objective measure of spasticity, the fact that BTX-A was dosed individually, and the heterogeneity of the sample regarding age, comorbidities, and time since stroke. Whereas individualization of dose and heterogeneity FIGURE 4 Box and Blocks Test (BBT) . No data were recorded for the three constraint-induced movement therapy participants on BBT at 12 wks. Each participant missed the session because of illness or other non-study-related event.
FIGURE 5
Motor Activity Log.
September 2007
Therapies for Upper-Limb Hemiparesis of the sample may be inherent limitations to any study of BTX-A in upper-limb hemiparesis attributable to stroke, many of the other aspects of this study could have been improved. Despite these limitations, this work brings to light several important points.
The finding that 4 of 12 subjects were able to reach minimal motor criteria with the combination of BTX-A and evidence-based exercise therapy was surprising and encouraging. It suggests that potential for improvement in hand function through CIMT or other interventions may be possible, even for those with very limited residual function. The finding that the presence of even a small amount of voluntary extension in at least three fingers at baseline predicted a response to therapy is not entirely unexpected. This validates the premise underlying the minimal motor criteria, that CIMT strengthens some minimum amount of intact connection between the motor cortex and the hand. This finding is also in accordance with Fritz et al., 50 who found that finger extension as defined by the ability to actively release a mass flexion grasp predicted WMFT outcomes for individuals enrolled in CIMT. However, perhaps more interesting is the response to therapy by the participant who had no detectable volitional control in the wrist, fingers, or thumb at baseline. In fact, while attempting finger extension, only cocontraction resulting in finger flexion could be generated. Nonetheless, this participant was able to meet minimal motor criteria with the application of BTX-A and evidence-based exercise therapy. This suggests that there may be untapped potential even in those with severely impaired hand function. Factors that might have contributed include the participant's younger age (37 yrs old compared with a mean of 57.9 yrs for the rest of the sample) and the fact that she was only 9 mos poststroke (compared with a mean of 50.18 mos for the rest of the sample).
The results of this study also support the concept that adjuvant therapies (in this case, the medication BTX-A plus exercise therapy, plus CIMT) may work in tandem to allow greater gains than would be expected by the application of any of the therapies individually. It seems that enrolling individuals in CIMT who are only able to meet MCC with the help of BTX-A and exercise therapy is feasible.
It may be useful to put this study in the context of the work of Brashear et al. 51 Brashear et al. randomized 126 individuals with poststroke spasticity of the wrist and fingers to receive 200 -240 units of BTX-A in a randomized, double-blind, placebo-controlled trial. The major outcomes included the Ashworth Scale and the Disability Assessment Scale (DAS). The DAS uses a zero-to three-point scale in which the rater assess the amount of disability in four domains: hygiene, dressing, limb position, and pain. Zero indicates no disability, and a score of 3 indicates severe disability. Significant decreases were noted in the Ashworth scores, and significant improvement (improvement of one of the selected domains of at least one point) was noted in the DAS. This wellcontrolled, industry-sponsored trial provides some evidence supporting the role of BTX-A in improving passive function in selected patients, although it can be criticized for not addressing or controlling exercise therapy after injection. Although the DAS is touted as a functional scale, two of its domains-pain and limb position-though of great value to patients, are not truly functional. In contrast, the trial reported here uses more precise measures of actual hand function, and explores the potential role of BTX-A in restoring active movement.
Any enthusiasm for these findings must be set against two hard realities. First, although there was improvement in motor function, the improvement gained was modest at best. An improvement from approximately 1 (very rarely) to 2 (rarely) on the MAL-Amount or from 41.6 -32.9 secs on the WMFT falls short of most affected individuals' ambitions. Second, even these modest gains regressed at 24 wks at the same time as spasticity was returning.
The investigators note that active functional task practice (reaching, grasping, and releasing), which is often the preferred therapeutic activity under motor learning theories, may not be practical for participants with very low levels of ability after BTX-A. For these people, alternative modes of practice may be more applicable. These may include therapies based on functional neuromuscular electrical stimulation. Second, even with our attempts at standardizing the resting state, we often witnessed significant variability in the expression of tone as measured by the Ashworth Scale. On an informal basis, we tried other methods to standardize the resting state, such as relaxation through visualization of calming environments. The results of this technique were no better than having the participants squeeze a tennis ball. The Ashworth Scale has both been touted and challenged as a reliable and reproducible test of spasticity in the poststroke hand. 52, 53 We have reservations regarding the precision and reproducibility of the Ashworth. Spasticity is a complex phenomenon that includes weakness, cocontraction, and exaggerated muscle stretch reflexes. Easily applied methods to quantify it are needed.
We also have noted variable response to BTX-A. Although most participants had a gradual improvement in hypertonicity during the initial 2 wks after injection, some participants demonstrated an immediate reduction in hypertonus. One participant's tone decreased from a score of 3 of 4 on the Ashworth to flaccidity in the fingers within minutes of BTX-A injection. The response lasted for weeks, after which hypertonus gradually reasserted itself. In another case, we noted improvement in tone and volitional control during the first 2 wks of exercise therapy that was lost during the second 2 wks, never to return.
The modest successes of this investigation suggest that a combination of therapeutic and pharmacologic approaches may be warranted in the treatment of hand paresis after stroke. However, the optimal combination awaits further investigation. The preferred dose and duration of post-BTX-A exercise therapy remains undefined. Modalities such as functional neuromuscular electrical stimulation may strengthen the response. Other medications that decrease spasticity or encourage neuroplasticity may be helpful. Clearly, further research is needed to extend the benefits of emerging therapies to those most severely affected by stroke. 
